Synriam, Ranbaxy's new anti-malarial drug combination, is the first new drug R&D project by an Indian generics company that's yielded a marketable drug. That's big in itself as various media reports have acknowledged. To me, its key value lies not so much in its "firstness." Its value is even greater as a case study - … Continue reading It takes a village : What Ranbaxy’s Synriam tells us
Apothecurry 